Best Practice & Research Clinical Endocrinology & Metabolism
Volume 24, Issue 2 , Pages 159-162 , April 2010

The quiet revolution

References 

  1. Ritchie R, Reynard J, Lewis T. Intersex and the Olympic games. Journal of The Royal Society of Medicine. 2008;101:395–399
  2. Rumbelow H. The middle sex. The Times. Nov 19th, 2009;
  3. Handley M. The IOC grapples with Olympic sex testing. Time Magazine. Feb 11th, 2010;
  4. Hughes IA, Houk C, Ahmed SF, et al. Consensus statement on management of intersex disorders. Archives of Disease in Childhood. 2006;91:554–563
  5. Atkins D, Best D, Briss PA, et al. Grading quality of evidence and strength of recommendations. British Medical Journal. 2004;328:1490
  6. Swiglo BA, Murad MH, Schünemann HJ, et al. A case for clarity, consistency, and helpfulness: state-of-the-art clinical practice guidelines in endocrinology using the grading of recommendations, assessment, development, and evaluation system. Journal of Clinical Endocrinology and Metabolism. 2008;93:666–673
  7. Pasterski V, Prentice P, Hughes I. Consequences of the Chicago Consensus on disorders of sex development (DSD): current practices in Europe. Archives of Disease in Childhood. 2009; Sep 22;[Epub ahead of print]
  8. Köhler B, Lin L, Mazen I, et al. The spectrum of phenotypes associated with mutations in steroidogenic factor 1 (SF-1, NR5A1, Ad4BP) includes severe penoscrotal hypospadias in 46, XY males without adrenal insufficiency. European Journal of Endocrinology. 2009;161:237–242
  9. Fukami M, Nishimura G, Homma K, et al. Cytochrome P450 oxidoreductase deficiency: identification and characterisation of biallelic mutations and genotype-phenotype correlations in 35 Japanese patients. Journal of Clinical Endocrinology and Metabolism. 2009;94:1723–1731
  10. Audi L, Fernandez-Cancio M, Carrascosa A, et al. Novel (60%) and recurrent (40%) androgen receptor gene mutations in a series of 59 patients with a 46, XY disorder of sex development. Journal of Clinical Endocrinology and Metabolism. 2010; Feb 11;[Epub ahead of print]
  11. Barbaro M, Balsamo A, Anderlid BM, et al. Characterization of deletions at 9p affecting the candidate regions for sex reversal and deletion 9p syndrome by MLPA. European Journal of Human Genetics. 2009;17:1439–1447
  12. Lonardo F, Cantalupo G, Ciavarella M, et al. Prenatal diagnosis of 46, XX testicular DSD. Molecular, cytogenetic, molecular-cytogenetic, and ultrasonographic evaluation. Prenatal Diagnosis. 2009;29:998–1001
  13. Wisniewski AB, Mazur T. 46, XY DSD with female or ambiguous external genitalia at birth due to androgen insensitivity syndrome, 5alpha-reductase-2 deficiency, or 17beta-hydroxysteroid dehydrogenase deficiency: a review of quality of life outcomes. International Journal of Pediatric Endocrinology. 2009; Sep 10;[Epub ahead of print]
  14. Schönbucher V, Schweizer K, Rustige L, et al. Sexual quality of life of individuals with 46, XY disorders of sex development. Journal of Sexual Medicine. 2010; Jan 6;[Epub ahead of print]
  15. Berra M, Liao LM, Creighton SM, et al. Long-term health issues of women with XY karyotype. Maturitas. 2010;65:172–178
  16. Nihoul-Fékété C. How to deal with congenital disorders of sex development in 2008 (DSD). European Journal of Pediatric Surgery. 2008;18:364–367
  17. Kojima Y, Mizuno K, Nakane A, et al. Long-term physical, hormonal and sexual outcome of males with disorders of sex development. Journal of Pediatric Surgery. 2009;44:1491–1496
  18. Wiesemann C, Ude-Koeller S, Sinnecker GH, et al. Ethical principles and recommendations for the medical management of differences of sex development (DSD)/intersex in children and adolescents. European Journal of Pediatrics. 2009; Oct 20;[Epub ahead of print]
  19. Liao LM, Green H, Creighton SM, et al. Service users’ experiences of obtaining and giving information about disorders of sex development. BJOG. 2010;117:193–199
  20. Feder EK. Normalizing medicine: between “intersexuals” and individuals with “disorders of sex development”. Health care analysis. 2009;17:134–143
  21. Polanco JC, Wilhelm D, Davidson TL, et al. Sox10 gain-of-function causes XX sex reversal in mice: implications for human 22q-linked disorders of sex development. Human Molecular Genetics. 2010;19:506–516
  22. Lecointre C, Pichon O, Hamel A, et al. Familial acampomelic form of campomelic dysplasia caused by a 960 kb deletion upstream of SOX9. American Journal of Medical Genetics. 2009;149A:1183–1189
  23. Lourenço D, Brauner R, De Perdigo A, et al. Mutations in NR5A1 associated with ovarian insufficiency. New England Journal of Medicine. 2009;360:1200–1210
  24. Uhlenhaut NH, Jakob S, Anlag K, et al. Somatic sex reprogramming of adult ovaries to testes by FOXL2 ablation. Cell. 2009;139:1–13
  25. Diamond M. Human intersexuality: difference or disorder?. Archives of Sexual Behavior. 2008;38:172
  26. Rivkees SA. Why the consensus for consensus?. Journal of Pediatric Endocrinology and Metabolism. 2008;21:503–505
  27. Crouch NS, Liao LM, Woodhouse CR, et al. Sexual function and genital sensitivity following feminizing genitoplasty for congenital adrenal hyperplasia. Journal of Urology. 2008;179:634–638
  28. Braga LH, Pippi Salle JL. Congenital adrenal hyperplasia: a critical appraisal of the evolution of feminizing genitoplasty and the controversies surrounding gender reassignment. European Journal of Pediatric Surgery. 2009;19:203–210
  29. de Vries AL, Doreleijers TA, Cohen-Kettenis PT. Disorders of sex development and gender identity outcome in adolescence: understanding gender identity development and its clinical implications. Pediatric Endocrinology Reviews. 2007;4:343–351
  30. Meyer-Bahlburg HF, Dolezal C, Baker SW, et al. Sexual orientation in women with classical or non-classical congenital adrenal hyperplasia as a function of degree of prenatal androgen excess. Archives of Sexual Behaviour. 2008;37:85–99
  31. Mathews GA, Fane BA, Conway GS, et al. Personality and congenital adrenal hyperplasia: possible effects of prenatal androgen exposure. Hormones and Behaviour. 2009;55:285–291
  32. Auyeung B, Baron-Cohen S, Ashwin E, et al. Fetal testosterone predicts sexually differentiated childhood behaviour in girls and in boys. Psychological Science. 2009;20:144–148
  33. van de Geijn GJ, Hersmus R, Loooijenga LH. Recent developments in testicular germ cell tumour research. Birth Defects Research Part C: Embryo Today. 2009;87:96–113
  34. Krentz AD, Murphy MW, Kim S, et al. The DM domain protein DMRT1 is a dose-sensitive regulator of fetal germ cell proliferation and pluripotency. Proceedings of the National Academy of Science USA. 2009;106:22323–22328
  35. Sonne SB, Perrett RM, Nielsen JE, et al. Analysis of SOX2 expression in developing human testis and germ cell neoplasia. International Journal of Developmental Biology. 2010;54:755–760
  36. Salonen J, Rajpert-De-Meyts E, Mannisto S, et al. Differential developmental expression of transcription factors GATA-4 and GATA-6, their cofactor FOG-2 and downstream target genes in testicular carcinoma in situ and germ cell tumours. European Journal of Endocrinology. 2010;162:625–631
  37. Warne GL, Raza J. Disorders of sex development (DSDs), their presentation and management in different cultures. Reviews in Endocrine and Metabolic Disorders. 2008;9:227–236

PII: S1521-690X(10)00032-1

doi: 10.1016/j.beem.2010.03.005

Best Practice & Research Clinical Endocrinology & Metabolism
Volume 24, Issue 2 , Pages 159-162 , April 2010

Article Tools